Apr. 29 at 12:31 PM
$HALO HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from
$90 to
$95.
http://Investing.com - H.C. Wainwright raised its price target on Halozyme Therapeutics (NASDAQ:HALO) to
$95 from
$90 on Tuesday while maintaining a Buy rating. According to InvestingPro analysis, the stock appears undervalued at current levels, placing it among companies on the most undervaluedlist.
Full-year 2026 consensus aligns broadly with the firm’s revenue, royalty and EBITDA framework, with FactSet at
$1.754 billion in total revenue,
$1.147 billion in royalties and
$1.164 billion in EBITDA versus H.C. Wainwright’s
$1.753 billion,
$1.146 billion and
$1.153 billion. The firm’s fiscal 2026 diluted EPS estimate is
$7.27 versus FactSet consensus of
$8.06.
https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-halozyme-stock-price-target-to-95-93CH-4644649
